Metastatic Castration Resistant Prostate Cancer Pipeline Insight

DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer  - Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Metastatic Castration-Resistant Prostate Cancer Understanding

Metastatic Castration-Resistant Prostate Cancer: Overview

Castrate-resistant prostate cancer (CRPC) is defined by disease progression despite androgen depletion therapy (ADT) and may present as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre-existing disease, and/or the appearance of new metastases. Advanced prostate cancer has been known under a number of names over the years, including hormone-resistant prostate cancer (HRPC) and androgen-insensitive prostate cancer (AIPC). Most recently, the terms CRPC or castration recurrent prostate cancer were introduced with the realization that intracrine/paracrine androgen production plays is significant in the resistant of prostate cancer cells to testosterone suppression therapy.

 

Prognosis is associated with several factors, including performance status, presence of bone pain, extent of disease on bone scan and serum alkaline phosphatase levels. Bone metastases will occur in 90% of men with CRPC and can produce significant morbidity, including pain, pathologic fractures, spinal cord compression and bone marrow failure. Paraneoplastic effects are also common, including anemia, weight loss, fatigue, hypercoagulability and increased susceptibility to infection

 

"Metastatic Castration-Resistant Prostate Cancer - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Castration-Resistant Prostate Cancer pipeline landscape is provided which includes the disease overview and Metastatic Castration-Resistant Prostate Cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Castration-Resistant Prostate Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence in Metastatic Castration-Resistant Prostate Cancer R&D. The therapies under development are focused on novel approaches to treat/improve in Metastatic Castration-Resistant Prostate Cancer.
  • In December 2021, Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0176 in Prostate Cancer. Accutar expects to begin enrollment of a Phase 1 clinical trial for AC0176 in the first quarter of 2022.
  • In January 2022, Hinova Pharmaceuticals announced that the first patient with metastatic castration-resistant prostate cancer (mCRPC) has been successfully dosed in a Phase I clinical trial of HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR). The ongoing open-label Phase I study in Australia will evaluate the safety, pharmacokinetics, and anti-tumor activity of HP518 in patients with mCRPC.

Metastatic Castration-Resistant Prostate Cancer Emerging Drug Chapters

This segment of the Metastatic Castration-Resistant Prostate Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Metastatic Castration-Resistant Prostate Cancer Emerging Drugs

 

Rucaparib: Clovis Oncology

Rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2 and 3 is being developed in multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway. Clovis holds global rights for rucaparib.

 

AC0176: Accutar Biotechnology

AC0176 is an orally bioavailable, chimeric degrader molecule designed to target and degrade androgen receptor (AR) with high potency, selectivity, and broad mutant coverage. AR is a hormone-regulated transcription factor, and its activation plays a critical role in prostate cancer initiation and progression. Accutar expects to begin enrollment of a Phase 1 clinical trial for AC0176 in the first quarter of 2022.

 

HP518: Hinova

HP518, discovered and developed by Hinova, is an orally bioavailable chimeric degrader targeting AR, with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.

 

XL092: Exelixis

XL092 is a next-generation oral tyrosine kinase inhibitor that targets kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. In designing XL092, Exelixis sought to build upon its extensive experience with cabozantinib, the company’s flagship medicine, retaining the target profile while improving key characteristics, including pharmacokinetic half-life. XL092 is currently being developed for the treatment of advanced solid tumors, including genitourinary cancers, as a monotherapy and in combination with immune checkpoint inhibitors. XL092 is the first internally discovered Exelixis compound to enter the clinic following the company’s reinitiation of drug-discovery activities.

Further product details are provided in the report……..

Metastatic Castration-Resistant Prostate Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Metastatic Castration-Resistant Prostate Cancer drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Metastatic Castration-Resistant Prostate Cancer

There are approx. 50 key companies which are developing the therapies for Metastatic Castration-Resistant Prostate Cancer. The companies which have their Metastatic Castration-Resistant Prostate Cancer drug candidates in the most advanced stage, i.e. Phase III include Veru Inc.

 

Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

Metastatic Castration-Resistant Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecule
  • Monoclonal Antibody
  • Immunotherapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Metastatic Castration-Resistant Prostate Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Castration-Resistant Prostate Cancer therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Castration-Resistant Prostate Cancer drugs.

Metastatic Castration-Resistant Prostate Cancer Report Insights

  • Metastatic Castration-Resistant Prostate Cancer  Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Metastatic Castration-Resistant Prostate Cancer Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Metastatic Castration-Resistant Prostate Cancer drugs?
  • How many Metastatic Castration-Resistant Prostate Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Castration-Resistant Prostate Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic Castration-Resistant Prostate Cancer?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Metastatic Castration-Resistant Prostate Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Metastatic Castration-Resistant Prostate Cancer: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Treatment

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Metastatic Castration-Resistant Prostate Cancer  – DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

VERU-111: Veru Inc

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

ZEN-3694: Zenith Epigenetics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

BAY2315497: Bayer

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Drug name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Metastatic Castration-Resistant Prostate Cancer Key Companies

Metastatic Castration-Resistant Prostate Cancer Key Products

Metastatic Castration-Resistant Prostate Cancer - Unmet Needs

Metastatic Castration-Resistant Prostate Cancer - Market Drivers and Barriers

Metastatic Castration-Resistant Prostate Cancer - Future Perspectives and Conclusion

Metastatic Castration-Resistant Prostate Cancer Analyst Views

Metastatic Castration-Resistant Prostate Cancer Key Companies

Appendix

List of Table

Table 1: Total Products for Metastatic Castration-Resistant Prostate Cancer

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type                                              

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Metastatic Castration-Resistant Prostate Cancer

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Zenith Epigenetics
• Surface Oncology
• Opna-IO LLC
• Regeneron Pharmaceuticals
• Veru Inc
• Constellation Pharmaceuticals
• Noxopharm Limited
• Immunic AG
• Accutar Biotechnology Inc
• Hinova pharmaceuticals
• Novartis
• Nuvation Bio
• Bayer

Forward to Friend

Need A Quote